Keywords: sanofi-aventis, eloxatin, gets, new, use, food, drug
Sanofi-Aventis' Eloxatin gets new use
Article | 15 November 2004
The US Food and Drug Administration has approved Sanofi-Aventis' Eloxatin (oxaliplatin), in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin), for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
